Clinical utility of CAR T cell therapy in brain tumors: Lessons learned from the past, current evidence and the future stakes.

IF 4.3 4区 医学 Q2 IMMUNOLOGY International Reviews of Immunology Pub Date : 2022-01-01 Epub Date: 2022-10-03 DOI:10.1080/08830185.2022.2125963
Abhishek Chatterjee, Sweety Asija, Sandhya Yadav, Rahul Purwar, Jayant S Goda
{"title":"Clinical utility of CAR T cell therapy in brain tumors: Lessons learned from the past, current evidence and the future stakes.","authors":"Abhishek Chatterjee,&nbsp;Sweety Asija,&nbsp;Sandhya Yadav,&nbsp;Rahul Purwar,&nbsp;Jayant S Goda","doi":"10.1080/08830185.2022.2125963","DOIUrl":null,"url":null,"abstract":"<p><p>The unprecedented clinical success of Chimeric Antigen Receptor (CAR) T cell therapy in hematological malignancies has led researchers to study its role in solid tumors. Although, its utility in solid tumors especially in neuroblastoma has begun to emerge, preclinical studies of its efficacy in other solid tumors like osteosarcomas or gliomas has caught the attention of oncologist to be tried in clinical trials. Malignant high-grade brain tumors like glioblastomas or midline gliomas in children represent some of the most difficult malignancies to be managed with conventionally available therapeutics, while relapsed gliomas continue to have the most dismal prognosis due to limited therapeutic options. Innovative therapies such as CAR T cells could give an additional leverage to the treating oncologists by potentially improving outcomes and ameliorating the toxicity of the currently available therapies. Moreover, CAR T cell therapy has the potential to be integrated into the therapeutic paradigm for aggressive gliomas in the near future. In this review we discuss the challenges in using CAR T cell therapy in brain tumors, enumerate the completed and ongoing clinical trials of different types of CAR T cell therapy for different brain tumors with special emphasis on glioblastoma and also discuss the future role of CAR T cells in Brain tumors.</p>","PeriodicalId":14333,"journal":{"name":"International Reviews of Immunology","volume":null,"pages":null},"PeriodicalIF":4.3000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Reviews of Immunology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/08830185.2022.2125963","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/10/3 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 2

Abstract

The unprecedented clinical success of Chimeric Antigen Receptor (CAR) T cell therapy in hematological malignancies has led researchers to study its role in solid tumors. Although, its utility in solid tumors especially in neuroblastoma has begun to emerge, preclinical studies of its efficacy in other solid tumors like osteosarcomas or gliomas has caught the attention of oncologist to be tried in clinical trials. Malignant high-grade brain tumors like glioblastomas or midline gliomas in children represent some of the most difficult malignancies to be managed with conventionally available therapeutics, while relapsed gliomas continue to have the most dismal prognosis due to limited therapeutic options. Innovative therapies such as CAR T cells could give an additional leverage to the treating oncologists by potentially improving outcomes and ameliorating the toxicity of the currently available therapies. Moreover, CAR T cell therapy has the potential to be integrated into the therapeutic paradigm for aggressive gliomas in the near future. In this review we discuss the challenges in using CAR T cell therapy in brain tumors, enumerate the completed and ongoing clinical trials of different types of CAR T cell therapy for different brain tumors with special emphasis on glioblastoma and also discuss the future role of CAR T cells in Brain tumors.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
CAR - T细胞治疗脑肿瘤的临床应用:从过去、当前证据和未来风险中吸取的教训。
嵌合抗原受体(CAR) T细胞治疗血液系统恶性肿瘤取得了前所未有的临床成功,这使得研究人员开始研究其在实体肿瘤中的作用。虽然其在实体瘤特别是神经母细胞瘤中的应用已经开始显现,但其在骨肉瘤或胶质瘤等其他实体瘤中的临床前研究已经引起了肿瘤学家的注意,需要在临床试验中进行尝试。恶性高级别脑肿瘤,如胶质母细胞瘤或儿童中线胶质瘤,是传统治疗方法最难治疗的恶性肿瘤,而复发的胶质瘤由于治疗选择有限,预后仍然最糟糕。CAR - T细胞等创新疗法可以通过潜在地改善结果和改善目前可用疗法的毒性,为治疗肿瘤学家提供额外的杠杆作用。此外,CAR - T细胞疗法有可能在不久的将来整合到侵袭性胶质瘤的治疗范例中。在这篇综述中,我们讨论了在脑肿瘤中使用CAR - T细胞治疗的挑战,列举了不同类型的CAR - T细胞治疗不同脑肿瘤的临床试验,特别强调了胶质母细胞瘤,并讨论了CAR - T细胞在脑肿瘤中的未来作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
11.00
自引率
4.00%
发文量
24
期刊介绍: This review journal provides the most current information on basic and translational research in immunology and related fields. In addition to invited reviews, the journal accepts for publication articles and editorials on relevant topics proposed by contributors. Each issue of International Reviews of Immunology contains both solicited and unsolicited review articles, editorials, and ''In-this-Issue'' highlights. The journal also hosts reviews that position the authors'' original work relative to advances in a given field, bridging the gap between annual reviews and the original research articles. This review series is relevant to all immunologists, molecular biologists, microbiologists, translational scientists, industry researchers, and physicians who work in basic and clinical immunology, inflammatory and allergic diseases, vaccines, and additional topics relevant to medical research and drug development that connect immunology to disciplines such as oncology, cardiovascular disease, and metabolic disorders. Covered in International Reviews of Immunology: Basic and developmental immunology (innate and adaptive immunity; inflammation; and tumor and microbial immunology); Clinical research (mechanisms of disease in man pertaining to infectious diseases, autoimmunity, allergy, oncology / immunology); and Translational research (relevant to biomarkers, diagnostics, vaccines, and drug development).
期刊最新文献
The NLRP3 inflammasome: Mechanisms of activation, regulation, and role in diseases. Transforming growth factor-β in tumor microenvironment: Understanding its impact on monocytes and macrophages for its targeting. FUNDC1 mediated mitochondria-dependent ferroptosis of epithelial cells in model of asthma by FBXL2/ar/GPX4 signaling pathway of SUMO1 at K136. Re-inventing traditional aluminum-based adjuvants: Insight into a century of advancements. The m6A methyltransferase METTL3 modifies Kcnk6 promoting on inflammation associated carcinogenesis is essential for colon homeostasis and defense system through histone lactylation dependent YTHDF2 binding.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1